AU2002233677A1 - Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression - Google Patents
Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expressionInfo
- Publication number
- AU2002233677A1 AU2002233677A1 AU2002233677A AU2002233677A AU2002233677A1 AU 2002233677 A1 AU2002233677 A1 AU 2002233677A1 AU 2002233677 A AU2002233677 A AU 2002233677A AU 2002233677 A AU2002233677 A AU 2002233677A AU 2002233677 A1 AU2002233677 A1 AU 2002233677A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibition
- angiogenesis inhibitor
- integrin expression
- inhibitor mediated
- examining effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004037 angiogenesis inhibitor Substances 0.000 title 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 230000001404 mediated Effects 0.000 title 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-44646 | 2001-02-21 | ||
| JP2001044646 | 2001-02-21 | ||
| PCT/JP2002/001562 WO2002066073A1 (en) | 2001-02-21 | 2002-02-21 | Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002233677A1 true AU2002233677A1 (en) | 2003-02-27 |
| AU2002233677B2 AU2002233677B2 (en) | 2005-01-06 |
Family
ID=18906601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002233677A Ceased AU2002233677B2 (en) | 2001-02-21 | 2002-02-21 | Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7122318B2 (en) |
| EP (2) | EP1362601B8 (en) |
| JP (1) | JP4255285B2 (en) |
| KR (1) | KR20030080013A (en) |
| CN (2) | CN101025419A (en) |
| AT (2) | ATE350660T1 (en) |
| AU (1) | AU2002233677B2 (en) |
| CA (1) | CA2438427C (en) |
| DE (2) | DE60229676D1 (en) |
| ES (2) | ES2280502T3 (en) |
| HK (2) | HK1059038A1 (en) |
| WO (1) | WO2002066073A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002233677B2 (en) | 2001-02-21 | 2005-01-06 | Eisai R&D Management Co., Ltd. | Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression |
| EP1430894A4 (en) * | 2001-09-05 | 2007-12-12 | Eisai R&D Man Co Ltd | Lymphocytic activation inhibitor and remedial agent for autoimmune disease |
| WO2005090297A1 (en) * | 2004-03-19 | 2005-09-29 | Biotie Therapies Corporation | Sulphonamide derivatives |
| WO2006090927A1 (en) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | Orexigenic action of sulfonamide compound |
| PL1893612T3 (en) | 2005-06-22 | 2012-01-31 | Plexxikon Inc | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
| FI20055498A0 (en) * | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamides |
| WO2007086605A1 (en) * | 2006-01-27 | 2007-08-02 | Eisai R & D Management Co., Ltd. | Method for prediction of the effect of sulfonamide compound |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| JP7189368B2 (en) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | Compounds for inhibition of alpha4beta7 integrin |
| EP3873884A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| KR102641718B1 (en) | 2018-10-30 | 2024-02-29 | 길리애드 사이언시즈, 인코포레이티드 | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| KR20220047323A (en) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Compounds for Inhibiting Alpha 4 Beta 7 Integrin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2128648C1 (en) * | 1993-09-10 | 1999-04-10 | Эйсай Ко. Лтд. | Sulfonamide derivatives, methods of their synthesis, a pharmaceutical composition and method of patient treatment |
| JP3545461B2 (en) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | Bicyclic heterocycle-containing sulfonamide derivatives |
| EP0889876B1 (en) | 1996-03-29 | 2001-07-25 | G.D. SEARLE & CO. | Meta-substituted phenylene sulphonamide derivatives |
| SK163598A3 (en) * | 1996-05-31 | 1999-06-11 | Scripps Research Inst | Methods and compositions useful for inhibition of angiogenesis |
| WO1998044797A1 (en) * | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
| US6096707A (en) | 1997-07-11 | 2000-08-01 | Biotie Therapies Ltd. | Integrin binding peptide and use thereof |
| US6291503B1 (en) * | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
| JP2000247949A (en) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | Indole compound containing sulfonamide |
| JP4039856B2 (en) | 2000-02-03 | 2008-01-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Integrin expression inhibitor |
| AU2002233677B2 (en) | 2001-02-21 | 2005-01-06 | Eisai R&D Management Co., Ltd. | Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression |
-
2002
- 2002-02-21 AU AU2002233677A patent/AU2002233677B2/en not_active Ceased
- 2002-02-21 US US10/468,615 patent/US7122318B2/en not_active Expired - Fee Related
- 2002-02-21 WO PCT/JP2002/001562 patent/WO2002066073A1/en active IP Right Grant
- 2002-02-21 CA CA2438427A patent/CA2438427C/en not_active Expired - Fee Related
- 2002-02-21 EP EP02700679A patent/EP1362601B8/en not_active Expired - Lifetime
- 2002-02-21 JP JP2002565631A patent/JP4255285B2/en not_active Expired - Fee Related
- 2002-02-21 AT AT02700679T patent/ATE350660T1/en active
- 2002-02-21 CN CNA2007100878177A patent/CN101025419A/en active Pending
- 2002-02-21 DE DE60229676T patent/DE60229676D1/en not_active Expired - Lifetime
- 2002-02-21 CN CNB028086376A patent/CN100384482C/en not_active Expired - Fee Related
- 2002-02-21 KR KR10-2003-7010944A patent/KR20030080013A/en active Search and Examination
- 2002-02-21 ES ES02700679T patent/ES2280502T3/en not_active Expired - Lifetime
- 2002-02-21 AT AT06013455T patent/ATE412895T1/en active
- 2002-02-21 DE DE60217300T patent/DE60217300T2/en not_active Expired - Lifetime
- 2002-02-21 EP EP06013455A patent/EP1742052B1/en not_active Expired - Lifetime
- 2002-02-21 ES ES06013455T patent/ES2317368T3/en not_active Expired - Lifetime
-
2004
- 2004-03-16 HK HK04101904A patent/HK1059038A1/en not_active IP Right Cessation
-
2007
- 2007-06-26 HK HK07106835A patent/HK1099363A1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002223504A1 (en) | Heterologous expression of taxanes | |
| AU2002305205A1 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
| AU2002333524A1 (en) | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors | |
| AU2002248185A1 (en) | Inhibition of angiogenesis by nucleic acids | |
| AU2001272852A1 (en) | Composition for the treatment of migraine | |
| AU2002233677A1 (en) | Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression | |
| AU2002216314A1 (en) | Heterocyclic angiogenesis inhibitors | |
| AU2002230531A1 (en) | Use of fgf-19 for inhibiting angiogenesis | |
| AU2001264173A1 (en) | Process for the isolation of lovastatin | |
| AU2002349621A1 (en) | Angiogenesis inhibitor | |
| AU2001230207A1 (en) | Method for the production of 1-amino-3-aryl-uracils | |
| AU2002356180A1 (en) | Methods for inhibiting angiogenesis | |
| AU2001293891A1 (en) | New combination for the treatment of asthma | |
| AU2001287668A1 (en) | Method for the sterilisation of objects | |
| EP1516620A4 (en) | Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor | |
| AUPQ885500A0 (en) | Enhancement of products | |
| AU2002361763A1 (en) | Method of reducing angiogenesis | |
| AU2003244347A1 (en) | Angiogenesis inhibitors | |
| AU2002337601A1 (en) | Process for the preparation of simvastatin | |
| EP1613268A4 (en) | Methods for inhibition of angiogenesis | |
| AU2002221566A1 (en) | Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders | |
| AU2002305868A1 (en) | Inhibitors of reggamma | |
| AU2002256967A1 (en) | Treating or reducing the risk of cardiovascular disease | |
| AU2003221324A1 (en) | Angiogenesis inhibitors | |
| AU2001228796A1 (en) | Process for manufacturing simvastatin and the novel intermediates |